The Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine was created following a large philanthropic gift from the Gottesman family to provide individual investigators and multidisciplinary teams with the resources needed to realize the promise of this emerging field. Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean, and faculty of Albert Einstein College of Medicine has designated space on the first floor of the Michael F. Price Center for Genetic and Translational Medicine and Harold and Muriel Block Research Pavilion, and renovated space in other buildings (Chanin, Ullmann, Kennedy) to establish an institute that would set the standard in stem cell research and regenerative medicine, nationally and internationally.
The Institute’s mission is: i) to advance the scientific knowledge in stem cell biology and breakthroughs in regenerative medicine through faculty interactions, research support and education; ii) to foster collaborations and innovations by bridging scientific fields and overcome natural departmental barriers; iii) to translate basic science discoveries into novel stem cell-based therapies that impact clinical care.
The Institute is building upon Einstein’s considerable strengths in human embryonic stem cell research and hematopoietic-, cancer-, and liver-directed cell therapy, as well as upon related research efforts in cardiovascular disease, diabetes, HIV/AIDS, and neuropsychiatric disease. Stem cell research at Einstein also benefits from the College of Medicine’s long-standing commitment to research with model organisms, including C. elegans, Drosophila, zebrafish, and mice.
About the Director
Paul S. Frenette, M.D. is the director of the Ruth L. and David S. Gottesman Institute for Stem Cell Biology aAbout the Institutend Regenerative Medicine. A leading stem cell and vascular biology researcher, Dr. Frenette spearheads Einstein's efforts to explore new research directions, while encouraging collaboration among researchers, recruiting new stem cell investigators and overseeing the establishment of shared core resources.
As a researcher, Dr. Frenette focuses on stem cell biology, vascular biology and inflammation. His work in blood stem cell trafficking – which investigates how stem cells migrate between the bone marrow and the blood – led to the recognition of an unexpected connection between the brain and bone marrow. His laboratory has shown that the release of hematopoietic stem cells in the blood follows circadian rhythms, which may impact stem cell therapy already used with cancer patients recovering from high doses of chemotherapy. His research group has recently identified Nestin+ mesenchymal stem cell as the target cell for neural signals and a novel HSC niche candidate in the bone marrow. Dr. Frenette’s vascular biology interests include studies on how vascular occlusions (sudden blockages in blood vessels) occur, particularly in sickle cell anemia. His paradigm-shifting findings revised the understanding of the mechanisms involved in this complex process. By identifying the critical role played by white blood cells, his work provides potential new therapies for the disease.
Dr. Frenette received a medical degree from Université Laval in Quebec City followed residency training at McGill University in Montreal, and completed a clinical fellowship in Hematology-Oncology at Tufts’ New England Medical Center in Boston. He then trained in the laboratories of Drs. Denisa Wagner (Harvard Medical School) and Richard Hynes (MIT). He was a faculty at Mount Sinai School of Medicine in New York from 1998-2010. Dr. Frenette was elected member of the American Society for Clinical Investigation (2004) and the Association of American Physicians (2010). He received the Gloire de l'Escolle Medal (Prix Grands Diplômés) from Université Laval in 2011. He has served on the editorial boards of Blood and JCI, the Medical Advisory Board of the New York Stem Cell Foundation, as chair of a scientific committee of the American Society of Hematology, and on multiple other panels at the NIH. He was recently elected vice-president of the International Society of Experimental Hematology (ISEH) and will become president of ISEH in 2015.
Dr. Frenette plans to leverage the College of Medicine’s distinctively collaborative environment and establish more frequent and robust research partnerships. By facilitating an extensive network of research relationships among basic, clinical and population researchers, the institute will expand the translational research and applications of its members and Einstein as a whole.